Prognostic Impact of Circulating Vitamin D and Genetic Variants in the Vitamin D Pathway in Glioblastoma
Clicks: 2
ID: 316532
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #28 of 104 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Vitamin D (VitD) signaling is implicated in cancer and immune regulation, but its role in glioblastoma (GBM) remains unclear. We investigated the prognostic impact of VitD levels, VDR expression, and polymorphisms in VitD-related genes in GBM. Methods Ninety GBM tumors (62 primary, 28 recurrent) were analyzed. Circulating 25-hydroxyvitamin D (25(OH)D) was measured in 54 cases; tumor VDR mRNA/protein, calcitriol, and CYP24A1/CYP27B1/CYP27A1 proteins were assessed. Whole-exome sequencing identified SNPs in VitD-pathway genes. Associations with overall (OS) and progression-free survival (PFS) were evaluated by Kaplan–Meier and Cox models. Transcriptomic profiles were explored by GSEA. Results Severe 25(OH)D deficiency (<10 ng/mL) was frequent (13 primary, 38.2%; 11, recurrent 55.0%). Patients with <10 ng/mL had significantly shorter OS than patients with higher levels (9 vs. 18 months; HR = 2.55, 95% CI 1.03–6.39, P = .045). High VDR protein was associated with longer PFS (13.1 vs. 4.7 months, P = .027). CYP27B1 variants rs4646536 and rs703842 were associated with shorter OS (∼9–11 vs. ∼23–24 months; P < .05), although statistical significance was attenuated after correction for multiple testing. Transcriptomic analysis showed that CYP27B1 wild-type tumors were enriched for immune-related programs (B/T/NK-cell cytotoxicity, interferon response, antigen presentation; FDR < 0.25), while SNP tumors displayed minimal activation, consistent with poorer outcomes. Conclusions Severe VitD deficiency (<10 ng/mL) and CYP27B1 variants (rs4646536, rs703842) were associated with poorer prognosis in GBM. These exploratory findings suggest that systemic VitD status and genetic variation in its metabolism may influence GBM progression and tumor–immune interactions, warranting validation in independent cohorts.
| Reference Key |
openalex_W7164027485
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mariangela Morelli, Francesca Di Lorenzo, Francesca Marchetto, Michele Menicagli, Sara Franceschi, Manuel Giacomarra, Carlo Gambacciani, Francesco Pieri, Francesco Pasqualetti, Paolo Aretini, Colin Gerard Egan, Silvia Trasciatti, Santina Battaglia, Linda Solfanelli, Fabrizio Nannipieri, Orazio Santo Santonocito, Anna Luisa Di Stefano, Francesca Lessi, Chiara Maria Mazzanti |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag158
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.